$KRTL Biotech Highlights Pediatric Product Line to
Post# of 99552
(Total Views: 49)
Posted On: 10/07/2025 10:21:38 AM
$KRTL Biotech Highlights Pediatric Product Line to Support Childhood Wellness and Global Public Health
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=494925
KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company"
announced today that its subsidiary, KRTL Biotech, Inc., is spotlighting its pediatric pharmaceutical portfolio, which includes a variety of formulations tailored to the unique needs of children and infants across Latin America. This line represents a vital component of the Company’s commitment to accessible healthcare and international health system alignment.
The pediatric catalog—developed and manufactured under GMP-certified protocols in Bolivia—includes antipyretics, analgesics, antitussives, antihistamines, multivitamins, and iron supplements, offered in syrups, drops, chewables, and powder sachets. Designed with age-appropriate dosing, flavoring, and formats, these products meet the therapeutic and practical requirements of pediatric patients, caregivers, and physicians alike.
"Children have specific healthcare needs, and our pediatric line is built with that sensitivity in mind," said Daniel Bishop, CEO of KRTL Biotech. "From formulation to packaging, every product is created to support early intervention, better adherence, and trusted outcomes."
These formulations are already used in Bolivian pharmacies and clinics, and many are supported by national procurement programs, reinforcing their safety, accessibility, and therapeutic value.
KRTL Biotech is currently preparing regulatory evaluation of select pediatric products for U.S. market entry, including possible alignment with OTC monograph pathways, where appropriate. The Company also sees strategic opportunity to supply these pediatric medicines to health ministries and NGOs throughout the Americas, particularly in support of public health campaigns targeting childhood nutrition and infection management.
"Pediatric care has always been central to our mission at SIGMA," said Patricia Wilstermann, CEO of SIGMA. "By delivering formulations designed specifically for children’s needs, we aim to support families, strengthen public health, and contribute to healthier futures for the next generation."
"Providing pediatric care options that are both high quality and affordable is central to our mission," said Cesar Herrera, CEO of KRTL Holding Group Inc. "This product line directly supports one of the most underserved and impactful areas of healthcare."
The pediatric portfolio includes:
Acetaminophen and ibuprofen syrups (fever and pain management)
Iron and multivitamin supplements (childhood development)
Antiallergics and cough syrups (respiratory support)
Digestive aids and electrolyte solutions (rehydration and GI care)
KRTL Biotech’s pediatric medicines exemplify the Company’s core values: scientific integrity, operational compliance, and cross-border scalability.
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=494925
KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company"
announced today that its subsidiary, KRTL Biotech, Inc., is spotlighting its pediatric pharmaceutical portfolio, which includes a variety of formulations tailored to the unique needs of children and infants across Latin America. This line represents a vital component of the Company’s commitment to accessible healthcare and international health system alignment. The pediatric catalog—developed and manufactured under GMP-certified protocols in Bolivia—includes antipyretics, analgesics, antitussives, antihistamines, multivitamins, and iron supplements, offered in syrups, drops, chewables, and powder sachets. Designed with age-appropriate dosing, flavoring, and formats, these products meet the therapeutic and practical requirements of pediatric patients, caregivers, and physicians alike.
"Children have specific healthcare needs, and our pediatric line is built with that sensitivity in mind," said Daniel Bishop, CEO of KRTL Biotech. "From formulation to packaging, every product is created to support early intervention, better adherence, and trusted outcomes."
These formulations are already used in Bolivian pharmacies and clinics, and many are supported by national procurement programs, reinforcing their safety, accessibility, and therapeutic value.
KRTL Biotech is currently preparing regulatory evaluation of select pediatric products for U.S. market entry, including possible alignment with OTC monograph pathways, where appropriate. The Company also sees strategic opportunity to supply these pediatric medicines to health ministries and NGOs throughout the Americas, particularly in support of public health campaigns targeting childhood nutrition and infection management.
"Pediatric care has always been central to our mission at SIGMA," said Patricia Wilstermann, CEO of SIGMA. "By delivering formulations designed specifically for children’s needs, we aim to support families, strengthen public health, and contribute to healthier futures for the next generation."
"Providing pediatric care options that are both high quality and affordable is central to our mission," said Cesar Herrera, CEO of KRTL Holding Group Inc. "This product line directly supports one of the most underserved and impactful areas of healthcare."
The pediatric portfolio includes:
Acetaminophen and ibuprofen syrups (fever and pain management)
Iron and multivitamin supplements (childhood development)
Antiallergics and cough syrups (respiratory support)
Digestive aids and electrolyte solutions (rehydration and GI care)
KRTL Biotech’s pediatric medicines exemplify the Company’s core values: scientific integrity, operational compliance, and cross-border scalability.
(0)
(0)